80% of China’s Clinical Trial Data Fraudulent!

A recent investigation of 1622 new drugs submitted to China’s State Food and Drug Administration (CFDA) has found that 1308 of those applications should be withdrawn for containing fabricated, flawed, or inadequate data from clinical trials. Find out more here. (Source: thebmj, October 2016)

You might also be interested in:

MNCs to Benefit from China’s Open Policy May 22, 2018
NPC’s Dubois: Article’s Authors ‘Used Flawed… March 13, 2019
Scale of Errors in Clinical Trial Registries Shocks Researchers April 21, 2018
RWE: Opportunity, Challenges and Sourcing Simplified November 30, 2018
BioMedCentral’s Trials Issues Call for Papers May 24, 2018
Pharmacy Benefit Managers: A Mechanism for Containing Costs or… October 1, 2018
China Aims to Expedite Price Cuts on Cancer Drugs July 10, 2018